Immunome, Inc. (NASDAQ:IMNM - Free Report) - Research analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for shares of Immunome in a report released on Wednesday, March 19th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.51) per share for the quarter, up from their previous estimate of ($0.72). Wedbush currently has a "Outperform" rating and a $33.00 target price on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Wedbush also issued estimates for Immunome's Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.80) EPS and FY2027 earnings at ($1.35) EPS.
A number of other equities analysts have also recently commented on the company. Lifesci Capital began coverage on Immunome in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price target on the stock. Guggenheim cut their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday, March 20th. Finally, Stephens reiterated an "overweight" rating and set a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $25.50.
Read Our Latest Report on Immunome
Immunome Price Performance
Immunome stock traded down $0.78 during mid-day trading on Monday, hitting $7.38. The company's stock had a trading volume of 607,317 shares, compared to its average volume of 827,029. The business has a 50 day moving average price of $9.72 and a 200-day moving average price of $11.49. Immunome has a 12 month low of $8.12 and a 12 month high of $26.70. The stock has a market cap of $641.26 million, a price-to-earnings ratio of -0.92 and a beta of 1.93.
Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The business had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million.
Insider Activity at Immunome
In related news, CEO Clay B. Siegall purchased 150,000 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the purchase, the chief executive officer now directly owns 669,636 shares in the company, valued at approximately $5,189,679. This represents a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.60% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in IMNM. BNP Paribas Financial Markets bought a new stake in shares of Immunome during the fourth quarter valued at approximately $70,000. KLP Kapitalforvaltning AS purchased a new position in Immunome during the fourth quarter valued at $75,000. AlphaQuest LLC boosted its holdings in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after buying an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after buying an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC bought a new position in shares of Immunome in the 4th quarter worth about $95,000. Hedge funds and other institutional investors own 44.58% of the company's stock.
About Immunome
(
Get Free Report)
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Featured Stories
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
